Mineralys Therapeutics (MLYS) stock, explained like you're 5

Is Mineralys Therapeutics a small, medium or large cap company?

No. Mineralys Therapeutics is a mid cap stock, not a large cap. Its market cap, which is the total value of all its shares, is about 2.1 billion dollars.

Here is how you can tell. Multiply the share price by the number of shares to get the market cap, then compare it to the usual sizes. Micro cap is under 300 million dollars, small cap is 300 million to 2 billion, mid cap is 2 to 10 billion, large cap is 10 billion and up, and mega cap is over 200 billion. Market caps move every day with the share price, so treat the number as a recent snapshot.

How Mineralys Therapeutics makes money

• Selling medicines, medical devices or healthcare services.
• Insurance premiums or hospital and clinic fees.
• Research and licensing deals.

What moves MLYS stock

• Results from clinical trials and approvals from regulators.
• Drug prices, insurance rules and government policy.
• Patents running out and new competing treatments.

In the news lately

• Mineralys Therapeutics (MLYS) Shares New Lorundrostat Data, Is The Stock A Bargain? (Yahoo Finance)
• Mineralys Therapeutics stock hits 52 week low at 20.4 USD (Investing.com)
• An officer's proposed share sale at Mineralys Therapeutics (MLYS) lists a $78.1K market value. (Stock Titan)
• (MLYS) Volatility Zones as Tactical Triggers (Stock Traders Daily)
• HC Wainwright & Co. reiterates Buy rating on Mineralys Therapeutics, $56 price target (TradingView)

Key terms to know before you follow MLYS

• Market cap
• P/E ratio
• EPS (earnings per share)
• Earnings report
• Volatility